PURPOSE\nConcurrent chemoradiotherapy (CCRT) is the standard management for locally advanced non-small cell lung cancer (LA-NSCLC), but the definite choice of Carboplatin or Cisplatin-based chemoradiotherapy as a treatment for elderly patients with LA-NSCLC has not yet been defined. In this study, we compared the efficacy and toxicity of Carboplatin vs. Cisplatin-based (CCRT) for elderly patients with LA-NSCLC. \nPATIENTS AND METHODS\nA study was conducted on 50 elderly patients (> 65 years) where 25 patients received Carboplatin (area under the curve[AUC] 2) and Paclitaxel (45 mg/m2) administered on days 1, 8, 15, 22, 28, and 35 over a 6-week period; concurrent thoracic radiotherapy (RT) followed by 2 cycles of Paclitaxel 200 mg/m2 and Carboplatin AUC 6. The other 25 patients received 50 mg/m2 of Cisplatin administered on days 1, 8, 29, and 36, and 50 mg/m2/day of Etoposide delivered on days 1–5 and 29–33; concurrent thoracic RT followed by Cisplatin 50 mg/m2 and Etoposide 50 mg/m2 for two additional cycles. Both groups received thoracic RT dose ranged from 60 Gy to 70 Gy in 2 Gy per fraction, five fractions a week over 6 to 7 weeks.\n \nRESULTS\nOverall survival for Carboplatin and Cisplatin-based regimens was 45.5% and 35.1% respectively as showed by Kaplan–Meier analysis with no significant differences and also the Cox regression analysis showed no significant differences (hazard ratio [HR]: 0.64, 95% CI: 0.27- 1.53) for patients treated with Carboplatin compared to Cisplatin-based treatment. Toxicities as anemia (OR: 0.25, 95% CI: 0.06-1.06), leucopenia (OR: 0.39, 95% CI: 0.16-0.92), thrombocytopenia (OR: 0.33, 95% CI: 0.10-1.09), nausea & vomiting (OR: 0.29, 95% CI: 0.11-0.75) and renal toxicity (OR: 0.17, 95% CI: 0.02-1.29) was significantly less in the Carboplatin group while other toxicities were the same in both groups. \n\nCONCLUSION\nBoth Carboplatin and Cisplatin-based regimens had the similar overall survival but the Carboplatin is less toxic when combined with RT in elderly LA-NSCLC treated patients.